A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI

Condition(s) targeted: Non-Urgent PCI

Intervention: clopidogrel (Drug); PRT060128 (Drug)

Phase: Phase 2

Status: Not yet recruiting

Sponsored by: Portola Pharmaceuticals

Official(s) and/or principal investigator(s):
Robert Harrington, MD, Study Chair, Affiliation: Duke University
Sunil V Rao, MD, Principal Investigator, Affiliation: Duke University
Robert C Welsh, MD, Principal Investigator, Affiliation: University of Alberta

Overall contact:
Gayle Paynter, RN BS MBA/MHA, Phone: 919-668-8641, Email: Gayle.e.paynter@duke.edu

This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI. After diagnostic angiography, patients scheduled for non-urgent PCI will be randomized to clopidogrel or to one of three dose levels of PRT060128.

Official title: A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: The study is not powered to examine a pre-specified endpoint; rather it is designed to explore a number of analyses to understand the clinical efficacy, biological activity, and tolerability and safety of PRT060128 in patients undergoing non-urgent PCI

Detailed description: Each patient randomized in this trial will participate for approximately 12 weeks, including a Screening period of up to 2 weeks, the acute peri-procedural phase, and a 60-day chronic treatment phase. The chronic phase includes daily in-hospital assessments until 24 Hours or Discharge (whichever comes first), a telephone follow-up on Day 7-10 post-Discharge, outpatient follow-up visits on Days 30 and 60-67, and a telephone follow-up 7 days following the last dose of study drug.

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- The patient is scheduled to undergo non-urgent PCI

- The patient is between 18 and 75 years of age (inclusive) and willing to comply with

the protocol

- Women of childbearing potential must have a negative serum or urine pregnancy test

within 24 hours of dosing. All patients must agree to use double barrier contraception during the study and for at least 4 weeks after their last dose.

- The patient or legally acceptable representative is able to read and give written

informed consent and has signed an informed consent form approved by the Investigator's IRB/IEC

Exclusion Criteria:

- Estimated or measured weight < 55 kg

- Acute non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation

myocardial infarction (STEMI) within 7 days prior to PCI

- Chronic total occlusion or unprotected left main stenting

- Cardiogenic shock (systolic blood pressure < 90 mm Hg requiring vasopressor or

hemodynamic support)

- Uncontrolled hypertension at the time of initial study drug administration defined as

measured systolic blood pressure > 190 mm Hg or diastolic blood pressure > 108 mm Hg

- Planned staged PCI

- Planned surgery during the study period

- Planned GP IIb/IIIa use

- Patient has received a clopidogrel loading dose (≥300 mg) within 7 days prior to

randomization; patients on maintenance clopidogrel may be enrolled

- The planned administration of the study-specified clopidogrel loading dose is >12

hours prior to PCI

- Administration of thrombolytic agents, fondaparinux, or oral anticoagulants (e. g.,

warfarin) within the 7 days prior to PCI

- Estimated creatinine clearance (e. g. Cockcroft-Gault) < 45 mL/min

- Anemia with hemoglobin level < 10 g/dL

- Thrombocytopenia (platelet count < 100,000/mm3)

- ALT and/or AST > 2. 5 x the ULN or other indication of clinically significant hepatic

dysfunction

- Facial or head trauma within the last 30 days

- Intraocular hemorrhage within the last 30 days

- Gastrointestinal bleeding within the last 30 days

- Active bleeding, or history of a bleeding disorder or known intracranial vascular

malformation

- History of any prior ischemic stroke or TIA within the last 5 years or intracranial

hemorrhage, neoplasm, or arteriovenous malformation

- Known allergy or contraindication to the components of PRT060128, aspirin, heparin,

clopidogrel, glycoprotein IIb/IIIa inhibitors, or to any contrast media

- Participation in any investigational drug study within 30 days prior to enrollment.

Participation in a device trial prior to enrollment is acceptable

- Prior participation in any study involving PRT060128

- Any condition which could interfere with, or the treatment for which might interfere

with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the patient's risk by participating in the study. This would include, but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy or any unexplained blackouts

Gayle Paynter, RN BS MBA/MHA, Phone: 919-668-8641, Email: Gayle.e.paynter@duke.edu

Starting date: October 2008
Ending date: September 2009
Last updated: September 10, 2008